Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38
Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.

En als donateur kunt u ook korting krijgen bij verschillende bedrijven:

https://kanker-actueel.nl/NL/voordelen-van-ops-lidmaatschap-op-een-rijtje-gezet-inclusief-hoe-het-kookboek-en-de-recepten-op-basis-van-uitgangspunten-van-houtsmullerdieet-te-downloaden-enof-in-te-zien.html

12 september 2016: Lees ook deze beide artikelen want wat zou er gebeuren als de immuuntherapie met hyperthermie zou worden gecombineerd? https://kanker-actueel.nl/NL/immuuntherapie-met-dendritische-killercells-dc-cik-geeft-veel-minder-kans-op-een-recidief-225-vs-462-procent-en-vergroot-significant-overall-overleving-met-25-procent-op-drie-jaars-meting.html

en dit artikel:

https://kanker-actueel.nl/NL/immuuntherapie-met-hpv-t-cellen-geeft-veelbelovende-resultaten-bij-vergevorderde-baarmoederhalskanker-met-twee-duurzame-complete-remissies-uit-9-patienten.html

12 september 2016: Bron: Int J Hyperthermia. 2016 Nov;32(7):801-8. doi: 10.1080/02656736.2016.1213430. Epub 2016 Aug 12

Wanneer patienten met baarmoederkanker naast hun behandeling met bestraling en chemo (cisplatin) samen aanvullend hyperthermie krijgen dan verbetert dat sterk de resultaten van de behandeling.

Op een 5-jaars meting van een 15 jarige gerandomiserde studie bij totaal 101 patiënten met baarmoederhalskanker in verschillende stadia waren dit de resultaten:

de ziektevrije tijd gaat van 60,6% naar 70,8%.
De kans op geen recidief gaat van 71.0% naar 80,1%.
De overall overleving gaat op 5 jaars meting van 64,8% naar 77,8%.
Complete Remissies - CR werden op de 5-jaars meting meer bereikt in de hyperthermiegroep dan in de controlegroiep: 88% versus 77.6% (adjusted odds ratio, 3.993; 95% confidence interval, 1.018-15.67; p = .047)
En dat allemaal zonder stijging van de bijwerkingen.

De studie is uitgevoerd in verschillende ziekenhuizen in Japan gedurende een periode van 15 jaar.

Lees ook dit studieverslag van een reviewstudie van hyperthermie naast bestraling en chemo:

Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses

Hier een aantal grafieken uit het volledige studierapport: http://www.tandfonline.com/doi/full/10.1080/02656736.2016.1213430 dat gratis is in te zien met mooie referentielijst welke onderaan dit artikel aan het abstract is toegevoegd. Kunt u wellicht eens meenemen naar uw behandelend arts mocht dit van toepassing zijn op u.

hyperthermie naast radiochemotherapie bij baarmoederkanker deelnemersschema Grafiek Deelnemerschema

Overall overleving

Ziektevrije overleving

Hier het abstract met de referentielijst:

whole-pelvic hyperthermia (HT) added to standard chemoradiotherapy (CRT) in locally advanced cervical cancer (CC) improved the complete remission rate - CR , disease free surviving andand overall surviving

2016 Nov;32(7):801-8. doi: 10.1080/02656736.2016.1213430. Epub 2016 Aug 12.

A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer.

Harima Y¹, Ohguri T², Imada H³, Sakurai H⁴, Ohno T⁵, Hiraki Y⁶, Tuji K⁷, Tanaka M⁸, Terashima H⁹.

Author information

Abstract

PURPOSE:

To evaluate the effectiveness of whole-pelvic hyperthermia (HT) added to standard chemoradiotherapy (CRT) in locally advanced cervical cancer (CC), by investigating the clinical response and survival of patients treated with cisplatin-based CRT vs. CRT with HT (CRT + HT).

MATERIALS AND METHODS:

This study was conducted at five hospitals in Japan between September 2001 and March 2015 in patients with the International Federation of Gynecology and Obstetrics stage IB (bulky)-IVA CC undergoing definitive CRT. After giving a written informed consent, patients were randomly allocated to two treatment groups: CRT and CRT + HT group. Overall survival (OS), disease-free survival (DFS), local relapse-free survival (LRFS), complete response (CR) rate and tolerability were evaluated.

RESULTS:

In total, 101 patients were treated. Patient characteristics, total dose of cisplatin and radiotherapy were similar for both groups. Although not statistically significant, the 5-year OS, DFS and LRFS in the CRT + HT group (77.8%, 70.8% and 80.1%, respectively) were better than those in the CRT group (64.8%, 60.6% and 71.0%, respectively). CR was significantly more likely to be achieved in patients in the CRT + HT group than in the CRT group (88% vs. 77.6%; adjusted odds ratio, 3.993; 95% confidence interval, 1.018-15.67; p = .047). CRT + HT was well tolerated and caused no additional acute or long-term toxicity compared with CRT alone.

CONCLUSIONS:

HT combined with CRT improved the CR rate of CRT in patients with locally advanced CC, however, could not improve survival outcomes. Further studies in larger samples are warranted.

KEYWORDS:

Cervical cancer; chemoradiotherapy; hyperthermia; randomisation

PMID:: 27418208
DOI:: 10.1080/02656736.2016.1213430

[PubMed - in process]

References

Arbyn M, Castellsague X, de Sanjose S, . (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675–86., , [Web of Science ®]
Rose PG, Bundy BN, Watkins EB, . (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–53., , [Web of Science ®]
Peters WA III, Liu PY, Barrett RJ II, . (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–13., [Web of Science ®]
Morris M, Eifel PJ, Lu J, . (1999). Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–43., , [Web of Science ®]
Keys HM, Bundy BN, Stehman FB 3rd, . (1999). Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–61., , [Web of Science ®]
Whitney CW, Sause W, Bundy BN Jr, . (1999). Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–48., [Web of Science ®]
Lutgens L, van der Zee J, Pijls-Johannesma M, . (2010). Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma. Cochrane Database Syst Rev CD006377.[Web of Science ®]
van der Zee J, Gonzalez Gonzalez D, van Rhoon GC, . (2000). Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355:1119–25., , [Web of Science ®]
Harima Y, Nagata K, Harima K, . (2001). A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 17:97–105.[Taylor & Francis Online], [Web of Science ®]
Urano M, Kahn J, Majima H, . (1990). The cytotoxic effect of cis-diamminedichloroplatinum(II) on cultured Chinese hamster ovary cells at elevated temperatures: Arrhenius plot analysis. Int J Hyperthermia 6:581–90.[Taylor & Francis Online], [Web of Science ®]
Rietbroek RC, Schilthuis MS, Bakker PJ, . (1997). Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 79:935–43., , [Web of Science ®]
de Wit R, van der Zee J, van der Burg ME, . (1999). A phase I/II study of combined weekly systemic cisplatin and locoregional hyperthermia in patients with previously irradiated recurrent carcinoma of the uterine cervix. Br J Cancer 80:1387–91., , [Web of Science ®]
Westermann A, Mella O, Van Der Zee J, . (2012). Long-term survival data of triple modality treatment of stage IIB–III–IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia – an update. Int J Hyperthermia 28:549–3.[Taylor & Francis Online], [Web of Science ®]
Benedet JL, Bender H, Jones H III, . (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209–62., , [Web of Science ®]
Bethesda MD. (1985). Dose and volume specification for reorting intracavitary therapy in gynecology. International Commission of Radiation Units and Measurements.
Fatehi D, van der Zee J, de Bruijne M, . (2007). RF-power and temperature data analysis of 444 patients with primary cervical cancer: deep hyperthermia using the Sigma-60 applicator is reproducible. Int J Hyperthermia 23:623–43.[Taylor & Francis Online], [Web of Science ®]
Trotti A, Byhardt R, Stetz J, . (2000). Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47., , [Web of Science ®]
Kaplan E, Meier P. (1958). Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457–81.[Taylor & Francis Online], [Web of Science ®]
Mantel N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–70.
Cox DR. (1992). Regression models and life-tables. Breakthroughs in statistics. New York: Springer; p. 527–41.
Cox D. (1958). The regression analysis of binary sequences (with discussion). J R Stat Soc B 20:215–42.
Vale C. (2008). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–12., , [Web of Science ®]
Vasanthan A, Mitsumori M, Park JH, . (2005). Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys 61:145–53., , [Web of Science ®]
Zolciak-Siwinska A, Piotrkowicz N, Jonska-Gmyrek J, . (2013). HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy – a phase III study. Radiother Oncol 109:194–9., , [Web of Science ®]
Grigsby PW, Heydon K, Mutch DG, . (2001). Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 51:982–7., , [Web of Science ®]
Grogan M, Thomas GM, Melamed I, . (1999). The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86:1528–36., , [Web of Science ®]
Bishop AJ, Allen PK, Klopp AH, . (2015). Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated? Int J Radiat Oncol Biol Phys 91:196–205., , [Web of Science ®]
Westermann AM, Jones EL, Schem BC, . (2005). First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer 104:763–70., , [Web of Science ®]
Feldmann HJ, Seegenschmiedt MH, Molls M. (1995). Hyperthermia – its actual role in radiation oncology. Part III: clinical rationale and results in deep seated tumors. Strahlenther Onkol 171:251–64.
Harima Y, Nagata K, Harima K, . (2000). Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer 88:132–8., , [Web of Science ®]
Eppink B, Krawczyk PM, Stap J, . (2012). Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia 28:509–17.[Taylor & Francis Online], [Web of Science ®]
Frey B, Weiss EM, Rubner Y, . (2012). Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia 28:528–42.[Taylor & Francis Online], [Web of Science ®]